(NASDAQ: DVAX) Dynavax Technologies's forecast annual revenue growth rate of 18.72% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.12%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.77%.
Dynavax Technologies's revenue in 2025 is $294,621,000.On average, 1 Wall Street analysts forecast DVAX's revenue for 2025 to be $39,800,731,443, with the lowest DVAX revenue forecast at $39,800,731,443, and the highest DVAX revenue forecast at $39,800,731,443. On average, 1 Wall Street analysts forecast DVAX's revenue for 2026 to be $50,157,687,505, with the lowest DVAX revenue forecast at $50,157,687,505, and the highest DVAX revenue forecast at $50,157,687,505.
In 2027, DVAX is forecast to generate $58,931,980,601 in revenue, with the lowest revenue forecast at $58,931,980,601 and the highest revenue forecast at $58,931,980,601.